CoChat
Sign Up
Cited by 20Sarcoma Diagnosis and TreatmentHER2/EGFR in Cancer ResearchBone Tumor Diagnosis and Treatments

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Prognostic significance of the expression of HER family members in primary osteosarcoma

Open access
Wang, Sheng‑Lin, Zhong, Guang‑Xian, Wang, Xin‑Wen, Yu, Feng‑Qiang, Weng, Dan‑Feng, Wang, Xin‑Xing, Lin, Jian‑Hua·2018·Oncology Letters
DOI 10.3892/ol.2018.8931PMC PMC6036504
Open this paper in CoChat — free accountOpen PDF

Abstract

The prognosis of patients with metastatic osteosarcoma is poor and has shown no significant improvement in nearly 20 years. The human epidermal growth factor (EGF) receptor (HER) family is frequently overexpressed in the majority of human carcinomas, and is involved in promoting the proliferation and survival of cancer cells. However, the role of EGFR and HER‑2 expression in osteosarcoma survival remains controversial and no previous study has simultaneously investigated the association of the expression of all the four HER family members with the prognostic significance of osteosarcoma. Therefore, the present study investigated the expression levels of the complete members of the HER family in osteosarcoma specimens, as well as their associations with the clinicopathological parameters, progression‑free survival (PFS) and overall survival (OS) time of patients with osteosarcoma. The expression of HER family members was detected in osteosarcoma tumor specimens from 60 patients using immunohistochemistry. The association of the expression of HER receptors in osteosarcoma with clinicopathological parameters was analyzed using χ2 test and Fishers exact test. Survival analyses were evaluated by Kaplan‑Meier method and Cox proportional hazards regression model. Overall, 18 (30%), 13 (22%), 23 (38%) and 19 (32%) patients presented with high expression of EGFR, HER‑2, HER‑3 and HER‑4, respectively, and the co‑expression of 2, 3 and all 4 members of the HER family was observed. High expression of EGFR and HER‑4 was associated with distant metastasis. High HER‑3 expression was significantly associated with an advanced Enneking stage and distant metastasis. Multivariate analysis demonstrated that the expression of EGFR, HER‑3, HER‑4, EGFR/HER‑3, EGFR/HER‑4 and HER‑3/HER‑4 was an independent predictor of poor PFS and OS time in osteosarcoma patients with stage I‑IIB disease. In patients with stage IIB osteosarcoma, the expression of HER‑4 and EGFR/HER‑4 demonstrated a more significant effect on PFS and OS time. In conclusion, therapies targeting EGFR, HER‑3 and HER‑4 may provide promising strategies for primary osteosarcoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3892/ol.2018.8931

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Immunohistochemical expression of HER family members in osteosarcoma specimens. (A) High EGFR expression: Predominantly membranous with some cytoplasmic brown staining (arrow). (B) Low EGFR expression. (C) High HER-2 expression: Predominantly cytoplasmic brown staining (arrow). (D) Low HER-2 expression. (E) High HER-3 expression: Predominantly nuclear and cytoplasmic brown staining (arrow). (F) Low HER-3 expression. (G) High HER-4 expression: Predominantly nuclear and cytoplasmic brown staining (arrow). (H) Low HER-4 expression. (I) Final HER expression score demonstrating no significant difference among the expression levels of the HER family members. The box-plot was obtained using GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA, USA) (original magnification of Fig. A-H, ×200). HER, human epidermal growth factor receptor.
Figure 1. Immunohistochemical expression of HER family members in osteosarcoma specimens. (A) High EGFR expression: Predominantly membranous with some cytoplasmic brown staining (arrow). (B) Low EGFR expression. (C) High HER-2 expression: Predominantly cytoplasmic brown staining (arrow). (D) Low HER-2 expression. (E) High HER-3 expression: Predominantly nuclear and cytoplasmic brown staining (arrow). (F) Low HER-3 expression. (G) High HER-4 expression: Predominantly nuclear and cytoplasmic brown staining (arrow). (H) Low HER-4 expression. (I) Final HER expression score demonstrating no significant difference among the expression levels of the HER family members. The box-plot was obtained using GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA, USA) (original magnification of Fig. A-H, ×200). HER, human epidermal growth factor receptor.CC BY-NC-ND · PubMed Central
Figure 2. Kaplan-Meier analyses of PFS and OS time in stage I–IIB osteosarcoma patients. Significant differences in (A) PFS (P=0.033) and (B) OS (P=0.041) time were found between the high and low EGFR expression groups. Significant differences in (C) PFS (P=0.001) and (D) OS (P=0.006) time were found between the high and low HER-3 expression groups. Significant differences in (E) PFS (P=0.010) and (F) OS (P=0.015) time were found between the high and low HER-4 expression groups. HER, human epidermal growth factor receptor; PFS, progression-free survival; OS, overall survival.
Figure 2. Kaplan-Meier analyses of PFS and OS time in stage I–IIB osteosarcoma patients. Significant differences in (A) PFS (P=0.033) and (B) OS (P=0.041) time were found between the high and low EGFR expression groups. Significant differences in (C) PFS (P=0.001) and (D) OS (P=0.006) time were found between the high and low HER-3 expression groups. Significant differences in (E) PFS (P=0.010) and (F) OS (P=0.015) time were found between the high and low HER-4 expression groups. HER, human epidermal growth factor receptor; PFS, progression-free survival; OS, overall survival.CC BY-NC-ND · PubMed Central
Figure 3. Kaplan-Meier analyses of PFS and OS time in stage IIB osteosarcoma patients. Significant differences of PFS time were found between the high and low (A) HER-4 (P=0.002) expression groups and (B) EGFR/HER-4 (P<0.001) expression groups. Significant differences of OS time were found between the high and low (C) HER-4 (P=0.011) expression groups and (D) EGFR/HER-4 (P<0.001) expression groups. HER, human epidermal growth factor receptor; PFS, progression-free survival; OS, overall survival.
Figure 3. Kaplan-Meier analyses of PFS and OS time in stage IIB osteosarcoma patients. Significant differences of PFS time were found between the high and low (A) HER-4 (P=0.002) expression groups and (B) EGFR/HER-4 (P<0.001) expression groups. Significant differences of OS time were found between the high and low (C) HER-4 (P=0.011) expression groups and (D) EGFR/HER-4 (P<0.001) expression groups. HER, human epidermal growth factor receptor; PFS, progression-free survival; OS, overall survival.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 41

  1. Zhou, 2014, Advances in targeted therapy for osteosarcoma, Discov Med, 17, 301
  2. De Luca, 2008, The role of the EGFR signaling in tumor microenvironment, J Cell Physiol, 214, 559, 10.1002/jcp.21260 · DOI
  3. Mendelsohn, 2006, Epidermal growth factor receptor targeting in cancer, Semin Oncol, 33, 369, 10.1053/j.seminoncol.2006.04.003 · DOI
  4. Renoir, 2013, Estrogen receptor signaling as a target for novel breast cancer therapeutics, Biochem Pharmacol, 85, 449, 10.1016/j.bcp.2012.10.018 · DOI
  5. Siu, 2014, Loss of EGFR signaling-regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance, Oncotarget, 5, 3770, 10.18632/oncotarget.1994 · DOI
  6. Xu, 2016, Dacomitinib, a new pan-EGFR inhibitor, is effective in killing ovarian cancer cells, Discov Med, 22, 297
  7. Do, 2009, The expression of epidermal growth factor receptor and its downstream signaling molecules in osteosarcoma, Int J Oncol, 34, 797
  8. Lee, 2012, Epidermal growth factor receptor: Is it a feasible target for the treatment of osteosarcoma?, Cancer Res Treat, 44, 202, 10.4143/crt.2012.44.3.202 · DOI
  9. Kersting, 2007, Epidermal growth factor receptor expression in high-grade osteosarcomas is associated with a good clinical outcome, Clin Cancer Res, 13, 2998, 10.1158/1078-0432.CCR-06-2432 · DOI
  10. Baxevanis, 2004, Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy, Cancer Immunol Immunother, 53, 166, 10.1007/s00262-003-0475-7 · DOI
  11. Abdou, 2016, The prognostic role of Ezrin and HER2/neu expression in osteosarcoma, Appl Immunohistochem Mol Morphol: AIMM, 24, 355, 10.1097/PAI.0000000000000197 · DOI
  12. Yalcin, 2008, C-erbB-2 expression and prognostic significance in osteosarcoma, Pediatric Blood Cancer, 51, 222, 10.1002/pbc.21576 · DOI
  13. Zhang, 2016, HER-2 expression in biopsy and surgical specimen on prognosis of osteosarcoma: A systematic review and meta-analysis of 16 studies, Medicine, 95, e3661, 10.1097/MD.0000000000003661 · DOI
  14. Akatsuka, 2002, ErbB2 expression is correlated with increased survival of patients with osteosarcoma, Cancer, 94, 1397, 10.1002/cncr.10360 · DOI
  15. Geller, 2010, HER-2 targeted treatment of osteosarcoma: The challenges of developing targeted therapy and prognostic factors for rare malignancies, Exp Opin Pharmacother, 11, 51, 10.1517/14656560903419614 · DOI
  16. Ma, 2014, Targeting of erbB3 receptor to overcome resistance in cancer treatment, Mol Cancer, 13, 105, 10.1186/1476-4598-13-105 · DOI
  17. Hassan, 2012, Cell surface receptor expression patterns in osteosarcoma, Cancer, 118, 740, 10.1002/cncr.26339 · DOI
  18. Hughes, 2004, Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma, Cancer Res, 64, 2047, 10.1158/0008-5472.CAN-03-3096 · DOI
  19. Hua, 2011, Abstract 197: Multi-cellular tumor spheroids in vitro model reveals a critical role of ERBB4 in survival of osteosarcoma, Cancer Res, 71, 197, 10.1158/1538-7445.AM2011-197 · DOI
  20. Enneking, 1980, A system for the surgical staging of musculoskeletal sarcoma, Clin Orthop Relat Res, 106, 10.1097/00003086-198011000-00013 · DOI
  21. Srirajaskanthan, 2010, Expression of the HER-1–4 family of receptor tyrosine kinases in neuroendocrine tumours, Oncol Rep, 23, 909, 10.3892/or_00000714 · DOI
  22. Liu, 2017, Survival time and prognostic factors of patients with initial noncurative colorectal liver metastases, Medicine (Baltimore), 96, e8831, 10.1097/MD.0000000000008831 · DOI
  23. Wu, 2007, Statistical analysis and correlation discovery of tumor respiratory motion, Phys Med Biol, 52, 4761, 10.1088/0031-9155/52/16/004 · DOI
  24. Nishikawa, 2013, Prognostic factors in patients with hepatitis B virus-related hepatocellular carcinoma undergoing nucleoside analog antiviral therapy, Oncol Lett, 6, 1213, 10.3892/ol.2013.1578 · DOI
  25. Pahl, 2012, Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma, Clin Cancer Res, 18, 432, 10.1158/1078-0432.CCR-11-2277 · DOI
  26. Huang, 2013, Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation, Cancer Res, 73, 824, 10.1158/0008-5472.CAN-12-1611 · DOI
  27. Huang, 2012, Stretch-induced fetal type II cell differentiation is mediated via ErbB1-ErbB4 interactions, J Biol Chem, 287, 18091, 10.1074/jbc.M111.313163 · DOI
  28. Silva, 2014, Cooverexpression of ERBB1 and ERBB4 receptors predicts poor clinical outcome in pN+ oral squamous cell carcinoma with extranodal spread, Clin Exp Metastasis, 31, 307, 10.1007/s10585-013-9629-y · DOI
  29. Anninga, 2004, Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas, Eur J Cancer, 40, 963, 10.1016/j.ejca.2003.10.025 · DOI
  30. Maitra, 2001, Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas, Cancer, 92, 677, 10.1002/1097-0142(20010801)92:3<677::AID-CNCR1370>3.0.CO;2-V · DOI
  31. Kilpatrick, 2001, Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma, Mod Pathol, 14, 1277, 10.1038/modpathol.3880474 · DOI
  32. Scotlandi, 2005, Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma, Eur J Cancer, 41, 1349, 10.1016/j.ejca.2005.03.015 · DOI
  33. Yoshida, 2012, Mechanism of resistance to trastuzumab and molecular sensitization via ADCC activation by exogenous expression of HER2-extracellular domain in human cancer cells, Cancer Immunol Immunother, 61, 1905, 10.1007/s00262-012-1249-x · DOI
  34. Long, 2014, Lapatinib alters the malignant phenotype of osteosarcoma cells via downregulation of the activity of the HER2-PI3K/AKT-FASN axis in vitro, Oncol Rep, 31, 328, 10.3892/or.2013.2825 · DOI
  35. Jullien, 2012, Downregulation of ErbB3 by Wnt3a contributes to wnt-induced osteoblast differentiation in mesenchymal cells, J Cell Biochem, 113, 2047, 10.1002/jcb.24076 · DOI
  36. Cai, 2010, Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma, J Pathol, 220, 24, 10.1002/path.2628 · DOI
  37. Xu, 2014, Down-regulation of miR-3928 promoted osteosarcoma growth, Cell Physiol Biochem, 33, 1547, 10.1159/000358718 · DOI
  38. Bianchi, 2006, ErbB-receptors expression and survival in breast carcinoma: A 15-year follow-up study, J Cell Physiol, 206, 702, 10.1002/jcp.20535 · DOI
  39. Karamouzis, 2007, Breast cancer: The upgraded role of HER-3 and HER-4, Int J Biochem Cell Biol, 39, 851, 10.1016/j.biocel.2006.11.017 · DOI
  40. Citri, 2006, EGF-ERBB signalling: Towards the systems level, Nat Rev Mol Cell Biol, 7, 505, 10.1038/nrm1962 · DOI
  41. Canfield, 2015, Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells, Cell Cycle, 14, 648, 10.4161/15384101.2014.994966 · DOI

Cited by

Sorted by citations

Metadata

Authors
Wang, S., Zhong, G., Wang, X., Yu, F., Weng, D., Wang, X., & Lin, J.
Affiliations
  • Department of Orthopedics, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350005, P.R. China
  • First Affiliated Hospital of Fujian Medical University (CN)
ORCID
Zhong, Guang‑Xian
Venue
Oncology Letters
Publisher
Spandidos Publications
Published
2018-06-08
Volume
16
Issue
2
Pages
2185-2194
ISSN
  • 1792-1074 (ISSN-L)
  • 1792-1082
DOI
10.3892/ol.2018.8931
PMC
PMC6036504
OpenAlex
W2807420926
Cited by
20
References
1
Citations by year
2024: 2 · 2023: 7 · 2021: 7 · 2020: 2 · 2019: 1 · 2018: 1
FWCI
2.07
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Oncology Letters (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (31571292)
  • Fujian Medical University
Topics
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
Keywords
primary osteosarcoma, ErbB receptors, EGFR, HER2, HER3, ErbB4, prognostic factors, progression-free survival, overall survival, distant metastasis, Enneking stage, targeted therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review